The reference treatment involves an antibody (immunotherapy) which neutralizes the effect of the IL-6.
Two antibodies may be used subject to availability: siltuximab (Sylvant®) and tocilizumab (RoActemra®). This treatment is suspensive and its duration is therefore indeterminate. It produces rapid effects but relapse is common if the treatment is withdrawn.
Corticosteroids or another antibody, rituximab (Mabthéra®) may be used to treat less severe forms.
The prognosis has improved significantly since the introduction of these new treatments but serious, resistant, life-threatening forms still exist.